Mr. Michael Frank reports
REVIVE THERAPEUTICS ENGAGES PHARMA-OLAM AND STRENGTHENS INFECTIOUS DISEASES CLINICAL DEVELOPMENT TEAM TO ADVANCE U.S. FDA CLINICAL STUDY FOR COVID-19
Revive Therapeutics Ltd. has retained Pharm-Olam LLC, with proven clinical experience in infectious diseases completing over 100 clinical studies in approximately 19,000 patients at over 2,000 clinical sites, to serve as the company's contract research organization (CRO) to advance the future clinical study for Bucillamine in the treatment of infectious diseases, including the coronavirus disease (COVID-19). In addition, Revive has added Dr. Kelly McKee Jr., MD, MPH, as chief scientific officer consultant and Dr. Onesmo Mpanju, PhD, as regulatory affairs consultant to the company's clinical development team.
"We are very pleased to have Pharm-Olam as our partner in guiding us towards our goal to investigate Bucillamine as a potential treatment for COVID-19 in a U.S. [Food and Drug Administration] clinical study and in other infectious diseases clinical studies in the future," said Michael Frank, chief executive officer of Revive. "Pharm-Olam has the proven experience in managing infectious disease clinical studies, a scalable ecosystem for expediting and completing clinical studies on time and on budget, and most importantly, they have an infectious disease team of experts with the addition of Dr. McKee and Dr. Mpanju, who will develop and oversee Revive's clinical study and its expeditious submission of our [investigational new drug] with the FDA."
Dr. McKee is currently senior scientific and medical adviser for Pharm-Olam. Previously, Dr. McKee served Pharm-Olam as chief medical officer and as vice-president, vaccines and public health, in the Infectious Diseases and Vaccines Center of Excellence at IQVIA (previously QuintilesIMS). He brings over 30 years of experience in research and development from the bench to the bedside, with specific expertise in vaccines, emerging diseases, biodefence, respiratory viral infections and sexually transmitted infections. His progressive clinical research experience began in 1981 at Fort Detrick, Frederick, Md., United States, where he served as a research virologist, immunologist, and head of the department of clinical investigation and medical division at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).
Dr. Onesmo Mpanju, PhD, has over 28 years of experience in biopharmaceutical research and development, including 18 years as a regulatory scientist. Previously, Dr. Mpanju was a reviewer at the U.S. FDA, Center for Biologics Evaluation & Research. His consulting experience includes non-commercial entities such as the U.S. National Institutes of Health, U.S. Army Medical Materiel Development Activity (USAMMDA), the Bill & Melinda Gates Foundation and others. Dr. Mpanju holds a PhD in experimental medicine (infectious diseases) from the University of British Columbia, Vancouver, Canada.
About Revive Therapeutics Ltd.
Revive is a life science company focused on the research and development of therapeutics for rare disorders and infectious diseases. Revive's technology is being advanced to fill the medical needs for diseases and disorders, such as pain, inflammation and wound care. Revive's cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas, such as liver disease. The company is also exploring the use of Bucillamine for the potential treatment of infectious diseases.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.